HFSA Scientific Statement: Update on Device Based Therapies in Heart Failure

Area of Science:

• Cardiology
• Biomedical Engineering

Background:

• Heart failure (HF) presents a growing global health challenge with significant mortality.
• Current pharmacological treatments like ARNIs, beta-blockers, MRAs, and SGLTis improve outcomes but leave residual risk.
• Device therapies including ICDs, CRT, CCM, and BAT offer additional management strategies.

Purpose of the Study:

• To outline unmet needs in chronic HF management.
• To review current data on novel device-based therapies.
• To propose a framework for integrating these devices into clinical practice.

Main Methods:

• Review of contemporary scientific literature and clinical trial data.
• Analysis of existing and emerging device-based therapies for HF.
• Development of a clinical integration framework.

Main Results:

• Despite advances, substantial residual risk remains in HFrEF and HFpEF.
• Novel devices like CCM and BAT show promise but lack guideline integration.
• A personalized, integrated approach combining pharmacotherapy and device therapy is crucial.

Conclusions:

• Early diagnosis, phenotyping, and patient stratification are essential for optimal HF care.
• Integrating novel device therapies requires further research into patient selection and device interactions.
• A comprehensive, personalized strategy is needed to address residual risks and improve HF outcomes.